Numinus Wellness Inc Stock Analysis:
Analysts rate Numinus Wellness Inc. with a Strong Buy rating and a 12-month average target price of $0.50 per share.
Based on the Numinus Wellness Inc stock forecasts from 1 analysts, the average analyst target price for Numinus Wellness Inc is CAD 0.50 over the next 12 months. Numinus Wellness Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Numinus Wellness Inc is Very Bearish, which is based on 0 positive signals and 4 negative signals. At the last closing, Numinus Wellness Inc’s stock price was CAD 0.27. Numinus Wellness Inc’s stock price has changed by -1.82% over the past week, -23.94% over the past month and -65.38% over the last year.
About Numinus Wellness Inc (NUMI:CA:TSX)
Numinus Wellness Inc. provides solutions to develop and deliver psychedelic-assisted psychotherapy and transform the mental health landscape. The company operates in two divisions, Salvation Botanicals and Numinus Health. The Salvation Botanicals division offers laboratory services, such as cultivation, analytical testing, product research and development, and ancillary services in the area of psychedelics; and full suite testing and custom testing of cannabis. The Numinus Health division provides supportive therapies and technologies to heal, connect, and grow with a focus on treating mental health and substance abuse; and services for psychotherapy, counselling, neurofeedback, physiotherapy, and other therapies. This division also offers training, facilities, and other operational resources to practitioners. The company is headquartered in Vancouver, Canada.
What we like:
There are no fundamental attributes that we particularly like.
What we don’t like:
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.